Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the litterature and personal experience;Le terapie biologiche con inibitori del TNF in reumatologia pediatrica. Revisione della letteratura ed esperienza personale

Reumatismo

Volumn 59, Issue 3, 2007, Pages 244-261

  Gerloni, V ^a   Pontikaki, I ^a   Gattinara, M ^a   Fantini, F ^a  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

Author keywords

Adalimumab; Anti TNF therapy; Etanercept; Infliximab; Juvenile idiopathic arthritis

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIVIRUS AGENT; ATLIZUMAB; CYCLOSPORIN; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANXIETY; ASTHENIA; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; BIOLOGICAL THERAPY; BONE MARROW SUPPRESSION; CHILD; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DERMATOMYOSITIS; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; HUMAN; HYPOGLOSSAL NERVE DISEASE; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INJECTION SITE REACTION; INSOMNIA; JOINT DESTRUCTION; JOINT RADIOGRAPHY; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; LONG TERM CARE; MIGRAINE; MONOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PANCYTOPENIA; PANIC; PARESTHESIA; PATHOGENESIS; POLYARTHRITIS; PROTEIN FUNCTION; PSYCHOSIS; REVIEW; RHEUMATIC DISEASE; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; SPONDYLOARTHROPATHY; THROMBOCYTOPENIA; TUBERCULOSIS; URTICARIA; UVEITIS; VERTIGO; ADOLESCENT; DISEASE PREDISPOSITION; DRUG ANTAGONISM; FEMALE; INFANT; IRIDOCYCLITIS; MALE; PRESCHOOL CHILD; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STATISTICS;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; AUTOIMMUNE DISEASES; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; INFANT; INFECTION; MALE; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS, ANTERIOR;

EID: 39549086403     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (150)

1. Brewer EJ, Bass J, Baum J, Cassidy JT, Fink C, Jacobs J, et al. Current proposed revision of JRA criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria committee of the American Rheumatism Section of the arthritis fundation. Arthritis Rheum 1977; 20 (suppl): 195-9.
2. Woo P. Nomenclature and classification of arthritis in children. In: Munthe E, ed. The care of rheumatic children. EULAR Bulletin No. 3. Basle: EULAR Publishers, 1978; 47-50.
3. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis. Durban, 1997. J Rheumatol 1998; 25: 1991-4.
4. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision. Edmonton, 2001. J Rheumatol 2004; 31: 390-2.
5. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. MTX in resistant juvenile rheumatoid arthritis: results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med 1992; 326: 1043-9.
6. van Rossum MA, Fiselier TJ, Franssen MJ, ten Cate R, van Suijlekom-Smit LW, Wulffraat NM, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998; 41: 808-16.
7. Giannini EH, Newman AJ, Fink CW. Low-dose MTX in children with JRA: results of a post-trial, long-term follow-up program. Arthritis Rheum 1993; 36: Suppl: S54. Abstract.
8. Halle F, Prieur AM. Evaluation of MTX in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol 1991; 9: 297-302.
9. Wallace CA, Sherry DD. Preliminary report of higher dose MTX treatment in juvenile rheumatoid arthritis. J Rheumatol 1992; 19: 1604-7.
10. Reiff A, Shaham B, Wood BP, Bernstein BH, Stanley P, Szer IS. High dose MTX in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 113-8.
11. Graham LD, Myones BL, Rivas-Chacon RF, Pachman LM. Morbidity associated with long-term MTX therapy in juvenile rheumatoid arthritis. J Pediatr 1992; 120: 468-73.
12. Wallace CA. The use of MTX in childhood rheumatic diseases. Arthritis Rheum 1998; 41: 381-9114.
13. Gerloni V, Cimaz R, Gattinara M, Arnoldi C, Pontikaki I, Fantini F. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford). 2001; 40: 907-13.
14. Ruperto N, Ravelli A, Castell E, Gerloni V, Haefner R, Malattia C, et al. Pediatric Rheumatology Collaborative Study Group (PRCSG); Paediatric Rheumatology International Trials Organisation (PRINTO). Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol 2006; 24: 599-605.
15. Brewer EJ, Giannini EH, Kuzmina N, Alekseev L. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: results of the USA-USSR double-blind placebo-controlled trial. N Engl J Med 1986; 314: 1269-76.
16. Giannini EH, Brewer EJ Jr, Kuzmina N, Shaikov A, Wallin B. Auranofin in the treatment of juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial. Arthritis Rheum 1990; 33: 466-76.
17. Silverman ED, Cawkwell GD, Lovell DJ, Laxer RM, Lehman TJ, Passo MH, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol 1994; 21: 2353-8.
18. Kuis W, Wulffraat NM, Petty RE. Autologous stem cell transplantation: an alternative for refractory juvenile chronic arthritis. Rheumatol 1999; 38: 737-8.
19. Bowyer SL, Roettcher PA, Higgins GC, Adams B, Myers LK, Wallace C, et al. Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol 2003; 30: 394-400.
20. De Benedetti F, Ravelli A, Martini A. Cytokines in juvenile rheumatoid arthritis. Curr Opin Rheumatol 1997; 9: 428-33.
21. Brennan FM, Chantry D, Jackson A, Maini RN. Inhibitory effect of TNF-α antibodies on synovial cell interleukin production. Lancet 1989; II: 244-7
22. Lepore L, Pennesi M, Saletta S, Perticarari S, Presani G, Prodan M. Study of IL-2, IL-6, IFNγ and β in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin Exp Rheumatol 1994; 12: 561-5.
23. Madson KL, Moore TL, Lawrence III JM, Osborn TG. Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis. J Rheumatol 1994; 21: 2359-63.
24. Prieur M, Kaufman MT, Griscelli C, Dayer JM. Specific interleukin 1 inhibitor in serum and urine of children with systemic JCA. Lancet 1987; 2: 1240-2
25. Mangge H, Kenzian H, Gallistl S, Neuwirth G, Liebmann P, Kaulfersch W, et al. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammatory parameters and clinical subtypes. Arthritis Rheum 1995; 38: 211-20.
26. Kutukculer N, Caglayan S, Aydogdu F. Study of Pro-Inflammatory (TNF-α, IL-1α, IL-6) and T-Cell-Derived (IL-2, IL-4) Cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clin Rheumatol 1998; 17: 288-92.
27. Rooney M, David J, Symons J, Di Giovine F, Varsani H, Woo P. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 1995; 34: 454-60.
28. Cope AP, Maini RN. Soluble tumor necrosis factor receptors in artlintis. J Rheumatol 1995; 22: 382-4.
29. Eberhard BA, Laxer RM, Andersson U, Silverman ED. Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. Clin Exp Immunol 1994; 96: 260-6.
30. Gattorno M, Picco P, Buoncompagni A, Stalla F, Facchetti P, Sormani MP, et al. Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Ann Rheum Dis 1996; 55: 243-7.
31. Muzaffer MA, Dayer JM, Feldman BM, Pruzanski W, Roux-Lombard P, Schneider R, et al. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis J Rheumatol 2002; 29: 1071-8.
32. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-86.
33. Konttinen L, Kankaanpaa E, Luosujarvi R, Blafield H, Vuori K, Hakala M, et al. ROB-FIN Study Group. Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study. Clin Rheumatol 2006; 25: 882-4.
34. Brennan FM, Cope AP, Katsikis P, Gibbons DL, Maini RN, Feldmann M. Selective immunosuppression of tumor necrosis factor-alpha in rheumatoid arthritis. In: L Adorini, ed. Selective immunosuppression: basic concepts and clinical applications (Chem Immunol), vol 60. Basel: Karger, 1995; 48-60.
35. Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 1991; 285: 199-212.
36. Rooney M, Varsani H, Martin K, Lombard PR, Dayer JM, Woo P. Tumour necrosis factor alpha and its soluble receptors in juvenile chronic arthritis. Rheumatology 2000; 39: 432-8.
37. Grom AA, Murray KJ, Luyrink L, Emery H, Passo MH, Glass DN, et al. Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996; 39: 1703-10.
38. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, el al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000; 342: 763-9.
39. Ruperto N, Lovell DJ, Cuttica R, Woo P, Espada G, Wouters C et al., for the Paediatric Rheumatology IN-ternational Trials Organization(PRINTO) and the Pediatric Rheumatology Collaborative Study Group Center (PRCSG). A randomized, placebo controlled trial of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis. Arthritis Rheum 2007 in press.
40. Ruperto N, Lovell DJ, Goodman S, Reiff A, Jung L, Nemcova D, et al. 48-week data from the study of Adalimumab in children with juvenile rheumatoid arthritis (JRA) Abstract EULAR-PRES 2006. Ann Rheum Dis 2006; 65 (Suppl II): 56.
41. Elliott MJ, Woo P, Charles P, Long-Fox A, Woody JN, Maini RN. Suppression of fever and the acutephase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). Br J Rheumatol 1997; 36: 589-93.
42. Meddeb N, Rammeh N, Gandoura N, Elleuch M, Cheour E, Sahli H, et al. [Juvenile Still's disease: a case report of treatment with infliximab] Therapie. 2002; 57: 407-8.
43. Billiau AD, Cornillie F, Wouters C. Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children. J Rheumatol 2002; 29: 1111-4.
44. ten Cate R, van Suijlekom-Smit LW, Brinkman DM, Bekkering WP, Jansen-van Wijngaarden CJ, Vossen JM. Etanercept in four children with therapy-resistant systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 2002; 41: 228-9.
45. Cairns AP, Taggart AJ. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. Ulster Med J 2002; 71: 101-5.
46. Barber J, Sheeran T, Mulherin D. Anti-tumour necrosis factor treatment in a patient with anorexia nervosa and juvenile idiopathic arthritis. Ann Rheum Dis 2003; 62: 490-1.
47. Mangge H, Heinzl B, Grubbauer HM, El-Shabrawi Y, Schauenstein K. Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol Int 2003; 23: 258-61.
48. Hung JJ, Huang JL. Etanercept therapy in children with juvenile rheumatoid arthritis. J Microbiol Immunol Infect 2005; 38: 444-6.
49. Liang TC, Yang YH, Lin YT, Chiang BL. Treatment with etanercept for patients with juvenile rheumatoid arthritis in Taiwan-a preliminary report. J Microbiol Immunol Infect 2005; 38: 447-50.
50. Takei S, Groh D, Bernstein B, Shaham B, Gallagher K, Reiff A. Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis. J Rheumatol 2001; 28: 1677-8.
51. Haapasaari J, Kautiainen H, Hannula S, Pohjankoski H, Hakala M. Good results from combining etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis. Clin Exp Rheumatol 2002; 20: 867-70.
52. Schmeling H, Mathony K, John V, Keysser G, Burdach S, Horneff G. A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study. Ann Rheum Dis 2001; 60: 410-2.
53. Kietz DA, Pepmueller PH, Moore TL. Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. J Rheumatol 2001; 28: 360-2.
54. Kietz DA, Pepmueller PH, Moore TL. Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 2002; 61: 171-3.
55. Russo RA, Katsicas MM, Zelazko M. Etanercept in systemic juvenile idiopathic arthritis. Clin Exp Rheumatol 2002; 20: 723-6.
56. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48: 1093-101.
57. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003; 62: 245-7.
58. Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A, et al. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, Infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum 2005; 52: 548-53.
59. Mori M, Takei S, Imagawa T, Imanaka H, Maeno N, Kurosawa R, et al. Pharmacokinetics, efficacy, and safety of short-term (12 weeks) etanercept for methotrexate-refractory polyarticular juvenile idiopathic arthritis in Japan. Mod Rheumatol 2005; 15: 397-404.
60. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. Paediatric Rheumatology Collaborative Group. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1638-44.
61. Nielsen S, Ruperto N, Simonini G, Alpigiani MG, Barcellona. R, Gerloni V, et al Preliminry evidence that Etanercept is more effective than Metothrexate in suppressing inflammation and in reducing radiographic progression in JIA. 2005 S82, abs. 128 ACR Annual Meeting 2005.
62. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich EC, Reiff A, et al. A phase 4 registry of etanercept in children with juvenile rheumatoid arthritis. Ann Rheum Dis 2006; 65 (Suppl II): 253.
63. Calvo I, Lopez B, Merino R, Garcia-Consuegra J, Moreno P, Lacruz L, Bravo B. Etanercept in patients with juvenile idiopathic arthritis: results of a retrospective multicenter registry Ann Rheum Dis 2006; 65 (Suppl II): 440.
64. Twilt M, Ten Cate R, Van Rossum MAJ, Wulffraat NM, De Bois MHW, Van Santen-Hoeufft MW, et al. Long term follow-up of etanercept in the treatment of juvenile idiopathic arthritis; the dutch national study. Ann Rheum Dis 2006; 65 (Suppl II): 572.
65. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
66. Ruperto N, Ravelli A, Falcini F, Lepore L, De Sanctis R, Zulian F, et al. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Ann Rheum Dis 1998; 57: 38-41.
67. Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, et al. Pediatric Rheumatology Collaborative Study Group. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003; 48: 218-26.
68. Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006; 54: 1987-94.
69. Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol 2005; 45: 246-56.
70. Prince FH, Twilt M, Jansen-Wijngaarden NC, van Suijlekom-Smit LW. Effectiveness of an once weekly double dose of etanercept in patients with JIA: a clinical study. Ann Rheum Dis 2007; 66: 704-5.
71. Horneff G, Moebius D, Michels H, Földvari I. Etanercept and leflunomide combination therapy in juvenile idiopathic arthritis (JIA). EULAR-PRES 2006. Ann Rheum Dis 2006; 65 (Suppl II): 439.
72. Simonini G, Giani T, Stagi S, de Martino M, Falcini F. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis. Rheumatology (Oxford) 2005; 44 (6): 777-80.
73. Tynjala P, Lahdenne P, Vahasalo P, Kautiainen H, Honkanen V. Impact of anti-TNF therapy on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis 2006; 65: 1044-9.
74. De Marco G, Gerloni V, Pontikaki I, Lurati A, Teruzzi B, Salmaso A, et al. Valutazione a lungo termine di infliximab nel trattamento dell'artrite idiopatica giovanile persistentemente attiva e refrattaria alle terapie convenzionali. Reumatismo 2007; 59: 50-6.
75. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly MTX in Rheumatoid Arthritis. Arthritis Rheum 1998; 41: 1552-63.
76. Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005; 32: 935-42.
77. Russo RA, Katsicas MM. Efficacy of anti-TNF therapy in subgroups of systemic-onset juvenile idiopathic arthritis. Abstract EULAR-PRES 2006 Ann Rheum Dis 2006; 65 (Suppl II): 567.
78. Katsicas MM, Russo RA. Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept. Clin Exp Rheumatol 2005; 23: 545-8.
79. Pontikaki I, Gerloni V, Gattinara M, Biggioggero M, Fantini F. Efficacy and safety of TNFα blockade in systemic JIA (soJIA) compared to the other JIA ILAR categories. results of an open monocentric long-term prospective study of 155 patients. Ann Rheum Dis 2006; 65 (Suppl II): 566.
80. de Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991; 34: 1158-63.
81. Keul R, Heinrich PC, Muller-newen G, Muller K, Woo P. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 1998; 10: 729-34.
82. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998; 25: 203-7.
83. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 818-25.
84. Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005; 7: R1281-8.
85. Prahalad S, Bove KE, Dickens D, Lovell DJ, Grom AA. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 2001; 28: 2120-4.
86. Makay B, Yilmaz S, Turkyilmaz Z, Unal N, Oren H, Unsal E. Etanercept for therapy-resistant macrophage activation syndrome. Pediatr Blood Cancer in press
87. Cortis E, Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr Suppl. 2006; 95: 38-41.
88. Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr 2006; 149: 833-6.
89. Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66: 548-50.
90. Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001; 44: 1411-5.
91. Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005; 53: 18-23.
92. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 2005; 44: 1008-11.
93. Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of TNFα blockade in JIA, in an open monocenter long-term prospective study of 163 patients. Submitted.
94. Richards JC, Tay-Kearney ML, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Experiment Ophthalmol 2005; 33: 461-8.
95. Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, et al. Tumour necrosis factor-α inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006; 45 (8): 982-9.
96. Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006; 113: 308-14.
97. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006; 113: 860-4.
98. Foeldvari I, Nielsen S, Kümmerle-Deschner J, Espada G, Horneff G, Bica B, et al. Tumor Necrosis Factor-alpha Blocker in Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Second-line Agents: Results of a Multinational Survey. J Rheumatol 2007; 34: 1146-50.
99. Kimura Y. Infliximab in refractory Bechet's disease in children. Pediatric Rheumatology Online Journal 2003; 1: 141.
100. Simonini G, et al. Substained Improvement of Refractory Chronic Uveitis on Infliximab treatment. Arthritis Rheum 2005; (Suppl) 52, S86.
101. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006; 149: 572-5.
102. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al. Adalimumab in the therapy of uveitis in childhood. Ophthalmol 2007; 91: 319-24.
103. Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol 2004; 31: 2055-61.
104. Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 2005; 52: 2103-8.
105. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005; 52: 2447-51.
106. Miller ML, et al. Experience with etanercept in chronic juvenile dermatomyositis (JDM). Arthritis Rheum 2000; 43: 1883.
107. Maillard SM, Wilkinson N, Riley P, et al. The treatment of severe idiopathic myositis with anti-TNF therapy. Arthritis Rheum 2002; 44 suppl. 9: S307.
108. Maillard SM, Wilkinson N, Riley P, Beresford M, Davidson J, Murray KJ. The treatment of persistent severe idiopathic inflammatory myositis with anti-TNF alpha therapy. Arthritis Rheum 2003; 46 suppl., S307.
109. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004; 31: 808-10.
110. Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki Syndrome. J Pediatr 2005; 146: 662-7.
111. Zulian F, Zanon G, Martini G, Mescoli G, Milanesi O. Efficacy of Infliximab in long-lasting refractory Kawasaki disease. Clin Exp Rheumatol 2006; 24: 453
112. Feinstein J, Arroyo R. Successful treatment of childhood onset refractory polyarteritis nodosa with tumor necrosis factor alpha blockade. J Clin Rheumatol 2005; 11: 219-22.
113. de Kort SW, van Rossum MA, ten Cate R. Infliximab in a child with therapy-resistant systemic vasculitis. Clin Rheumatol 2006; 25: 769-71.
114. Brik R, Gepstein V, Shahar E, Goldsher D, Berkovitz D. Tumor necrosis factor blockade in the management of children with orphan diseases. Clin Rheumatol 2007 in press.
115. Drewe E, McDermott EM, Powell RJ. Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med 2000; 343: 1044-5.
116. Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore). 2002; 81: 349-68.
117. Weyhreter H, Schwartz M, Kristensen TD, Valerius NH, Paerregaard A. A new mutation causing autosomal dominant periodic fever syndrome in a Danish family. J Pediatr 2003; 142: 191-3.
118. Aróstegui JI, Solís P, Aldea A, Cantero T, Rius J, Bahíllo P, et al. Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic sindrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response. Eur J Pediatr 2005; 164: 13-6.
119. Drewe E, McDermott EM, Powell PT, Isaacs JD, Powell RJ. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford). 2003; 42: 235-9.
120. Marchetti F, Barbi E, Tommasini A, Oretti C, Ventura A. Inefficacy of etanercept in a child with hyper- IgD syndrome and periodic fever. Clin Exp Rheumatol 2004; 22: 791-2.
121. Arkwright PD, McDermott MF, Houten SM, Frenkel J, Waterham HR, Aganna E, et al. Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol. 2002; 130: 484-8.
122. Cortis E, De Benedetti F, Insalaco A, Cioschi S, Muratori F, D'Urbano LE, et al. Abnormal production of tumor necrosis factor (TNF) alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome. J Pediatr 2004; 145: 851-5.
123. Federico G, Rigante D, Pugliese AL, Ranno O, Catania S, Stabile A. Etanercept induces improvement of arthropathy in chronic infantile neurological cutaneous articular (CINCA) syndrome. Scand J Rheumatol 2003; 32: 312-4.
124. Dekker L, Armbrust W, Rademaker CM, Prakken B, Kuis W, Wulffraat NM. Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2004; 22: 252-8.
125. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. Consensus Development Conference. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005; 34: 819-36.
126. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti tumour necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000; 343: 1594-601.
127. Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 2003; 30: 401-3.
128. Skytta E, Pohjankoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 2000; 18: 533-4.
129. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000; 59: 1341-59.
130. Lobel EZ, Korelitz BI, Warman JI Red man syndrome and infliximab. J Clin Gastroenterol 2003; 36: 186.
131. Becker M, Rosé CD, McIlvain-Simpson G. Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis. J Rheumatol 2004; 31: 2529-30.
132. Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol 2004 (5 Suppl 35); S134-40.
133. Tauber T, Turetz J, Barash J, Avni I, Morad Y. Optic neuritis associated with etanercept therapy for juvenile arthritis. J AAPOS. 2006; 10: 26-9.
134. Havell EA. Anche le esperienze nell'AIG, come quelle nell'AR dell'adulto. Evidence that tumour necrosis factor has an important role in a antibacterial resistance. J Immunol 1989; 143: 2894-9.
135. Pfeffer K, Matsuyama T, Kündig TM, Wakeham A, Kishihara K, Shahinian A, et al. Mice deficient for the 55kd tumour necrosis factor receptor are resistant to endotoxic shock, yet succumb to L monocytogenes infection. Cell 1993; 73: 457-67.
136. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 2005; 84: 291-302.
137. Elwood RL, Pelszynski MM, Corman LI. Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept. Pediatr Infect Dis J 2003; 22: 286-8.
138. Armbrust W, Kamphuis SS, Wolfs TW, Fiselier TJ, Nikkels PG, Kuis W, et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 2004; 43: 527-9.
139. Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, et al. Chronic exposure to TNFa in vitro impairs the activation of T cells through the T cell receptor/CD3 complex: reversal in vivo by anti-TNFa antibody in patients with rheumatoid arthritis. J Clin Invest 1994; 94: 749-60.
140. Moreland LW. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. Pharmacoeconomics 2004 (2 Suppl); 39-53.
141. Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF. Tuberculosis associated with therapy against tumour necrosis factor alpha. Arthritis Rheum 2005; 52: 2968-74.
142. Winthrop KL. Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor alpha. Ann Rheum Dis 2005; 64 Suppl 4: iv 29-30.
143. Myers A, Clark J, Foster H. Tuberculosis and treatment with infliximab. N Engl J Med 2002; 346: 623-6.
144. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005; 52: 2192-201.
145. Bloom BJ. Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43: 2606-8.
146. Lepore L, Marchetti F, Facchini S, Leone V, Ventura A. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. Clin Exp Rheumatol 2003; 21: 276-7.
147. Mor A, Bingham C 3rd, Barisoni L, Lydon E, Belmont HM. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 2005; 32: 740-3.
148. Saint Marcoux B, De Bandt M, CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 2006; 73: 710-3.
149. Ruemelle FM, Prieur AM, Talbotec C, Goulet O, Schmitz J. Development of Crhon disease during anti- TNF-alpha therapy in a child with juvenile idiopatic arthritis. J Pediatr Gastroenterol Nutr 2004; 39: 203-6.
150. Thayu M, Markowitz JE, Mamula P, Russo PA, Muinos WI, Baldassano RN. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005; 40: 220-2.